Search results for: Health Data and Statistics

Analysing Global Immunisation Expenditure

15 April 2025

…(such as COVID-19, pneumococcal and herpes zoster) and adolescent programmes (such as meningococcal). Data gaps hinder effective policy-making and monitoring Data on immunisation spending by age group and programme is…

The case for adopting a broader perspective on value in Health Technology Assessment

3 March 2026

…targeted approach balances ambition with feasibility and incentivises data collection to reduce uncertainty over time. This Contract Research Report was commissioned and funded by AstraZeneca and Daiichi Sankyo and was…

Privacy Policy

…sponsors (the “Data Controller”). Handling of such data is only conducted with the informed consent of the participant and in compliance with the Data Protection Act and the General Data…

Atherosclerotic cardiovascular disease (ASCVD) costs the world $680 billion a year in healthcare – roughly the size of Sweden’s entire economy, new research finds 

31 March 2026

…forefront of all we do. OHE provides independent and pioneering resources, research and analyses in health economics, health policy and health statistics. Our work informs decision–making about health care and…

Socio-Economic Value of Adult Immunisation Programmes

18 April 2024

…a powerful tool. A prevention mindset is often adopted in other sectors beyond healthcare (e.g. road safety and workforce health and safety) to prevent harmful health outcomes and productivity losses and…

New research reveals, in carers’ own words, the multidimensional burden of caring for leukemia patients

20 November 2025

…to improve health care through pioneering and innovative research, analysis, and education.    As a global thought leader and publisher in the economics of health, health care, and life sciences, we…

Navigating the Intersection of Healthcare and Environmental Sustainability: ISPOR Europe round-up on the inclusion of environmental impact in HTA

17 January 2024

…of health and the environment, the industry’s collaborative efforts, innovative solutions, and commitment to change offer the potential for a greener and healthier future for all. However, there are still…

Global rare‑disease policy shifts: what are the implications for equitable access to orphan medicines?

1 March 2026

…therefore especially sensitive to regulatory and policy changes. However, regulatory incentives for orphan drug research and development (R&D) are often not matched by Health Technology Assessment (HTA) and Pricing and…

New evaluation model finds widespread adoption of cell and gene therapies may unlock billions for the UK economy

20 October 2025

…in health economics, health policy and health statistics. Our work informs decision–making about health care and pharmaceutical issues at a global level.    All of our work is available for free…